section name header

Pronunciation ⬇

e-toe-POE-side

Classifications ⬆ ⬇

Therapeutic Classification: antineoplastics

Pharmacologic Classification: podophyllotoxin derivatives

Indications ⬆ ⬇

High Alert


Unlabeled Use:

Action ⬆ ⬇

  • Damages DNA before mitosis (cycle-dependent and phase-specific).
Therapeutic effects:
  • Death of rapidly replicating cells, particularly malignant ones.

Pharmacokinetics ⬆ ⬇

Absorption: Variably absorbed after oral administration (bioavailability ~50%). IV administration results in complete bioavailability.

Distribution: Rapidly distributed; poorly enters the CSF; probably crosses placenta; enters breast milk.

Protein Binding: 97%.

Metabolism/Excretion: Some metabolism by the liver with biliary excretion, 44% excreted in feces; 45% excreted unchanged by the kidneys.

Half-Life: 4–11 hr.

Time/Action Profile ⬆ ⬇

(noted as effects on blood counts)

ROUTEONSETPEAKDURATION
POunknown7–14 days (granulocytes) 9–16 days (platelets)20 days
IVunknown7–14 days (granulocytes) 9–16 days (platelets)20 days



Contraind./Precautions ⬆ ⬇

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects ⬆ ⬇

Interactions ⬆ ⬇

Drug-drug:

Route/Dosage ⬆ ⬇

Testicular Neoplasms

Small-Cell Carcinoma of the Lung

Availability ⬆ ⬇

(Generic available)

Assessment ⬆ ⬇

Lab Test Considerations:

Implementation ⬆ ⬇

IV Administration:

Patient/Family Teaching ⬆ ⬇

Evaluation/Desired Outcomes ⬆ ⬇

Canadian Brand Names ⬆

Vepesid